Background: Serum specific IgE to AraH2 has been well-established in the diagnosis and management of peanut allergy. Historically, patients with a skin prick test result above 8 mm have had peanut oral food challenges deferred due to a less than 5% chance of passing.
Aim: To ascertain if a negative AraH2 (<1 kU/ml) is associated with an increased chance of tolerance in the traditional 95% PPV cohort. To describe the patient characteristics of >8mm who experience anaphylaxis.
Method:
We reviewed the medical records of all patients who underwent serum AraH2 testing at the Epworth Hospital in Melbourne between 2013 and 2018, focusing on the >8 mm cohort. Patient demographics and details of challenge outcomes were extracted.
Results: 33 patients with a SPT above 8 underwent oral food challenge with a positive rate of 63%. A negative AraH2 had a NPV of 37% in this population. 5 patients experienced anaphylaxis in this cohort but none had severe anaphylaxis. There was no correlation between any specific patient characteristic (sensitization versus previous allergy) and risk of a positive challenge and/or anaphylaxis. There was trend towards higher threshold dose for positive challenges in this cohort and no patient with a negative AraH2 and anaphylaxis reacted on their first dose.
Conclusion:
AraH2 component resolved testing has potential utility in predicting tolerance in the high probability peanut sensitized cohort. Background: In children, oral food challenges are the 'gold standard' to determine allergic reactions against a food. However, the recent death of a 3-year-old boy during a routine oral food challenge raises questions on the residual allergen content in the food challenge materials. The present study was undertaken to understand the levels of major milk allergens in uncooked and baked milk containing foods, including recipes used for making oral food challenge materials. We also sought to determine the variability in allergen levels between different recipes and repeated batches of the same recipes.
P2 LEVELS OF MILK ALLERGEN IN BAKED ORAL FOOD CHALLENGE MATERIALS
Methods: We measured beta-lactoglobulin (Bos d 5) and for beta-casein (Bos d 11) using a sandwich ELISA in uncooked and baked muffin mix. The assay had a lower limit of detection (LLOD) of 0.19 ng/ml and 31.25 ng/ml respectively. Allergens from the uncooked and baked muffin were extracted into a buffer and then assayed by ELISA. Intra and inter muffin variability was compared. As well as variability from one baker to another.
Results: Our observations indicated that Bos d 5 (beta-lactoglobulin) was reduced from 1200 μg/g in uncooked muffin mix to 2 μg/g in baked muffin, representing a 99% decrease after baking. Conversely the level of Bos d 11 (beta-casein) decreased from 1000 μg/g in uncooked muffin mix to 800 μg/g. Representing only a~20% decrease in allergen after baking.
Conclusions: The level of major milk allergen Bos d 11 remained high within the baked foods, including those used as oral food challenge material. These findings highlight the differences between specific milk allergen molecules and demonstrates the need to assess each potential allergen individually in these oral food challenge materials. These measurements could improve safety of food products in clinical practices for oral food challenges. Background: Research suggests introduction of peanut in high risk infants before 12 months of age reduces incidence of peanut allergy. However, the safety of implementing this recommendation without prior screening, has not been prospectively studied.
P3 RATES OF ALLERGIC REACTIONS IN HIGH RISK INFANTS DURING FIRST INTRODUCTION OF PEANUT

Methods:
The Promoting Introduction to Prevent Peanut Allergy (PIPPA) project provides a supervised environment for high risk infants to introduce peanut before 12 months of age. High risk infants are defined as having: a personal history of eczema or another food allergy; first degree relative with a food allergy; and/or two first degree relatives with any atopic diseases. Parents mixed 2 teaspoons of peanut butter into the infant's usual food (~1/4 cup) to create a "peanut mixture". The three-step process for introduction involved mucosal lip rub with peanut butter, ingestion of 1 teaspoon of the peanut mixture and then ingestion of the remainder of the mixture, with 15-minute intervals between steps. Introduction was stopped for any objective allergic reactions.
Results: 140 high risk infants have attended the PIPPA clinic. Fourteen infants (10%) had an allergic reaction; there were 13 mild cutaneous reactions (9.3% of all participants) and one case of anaphylaxis (0.7% of participants). Of the 13 mild cutaneous reactions observed, 10 (77%) resolved without treatment and the remaining three (23%) were treated with oral antihistamine. The case of anaphylaxis was treated with a single dose of intramuscular adrenaline. Of the 14 reactions, seven (54%) occurred after
Step 1, five (38%) after Step 2 and one (8%) after Step 3.
Conclusions: For most high risk infants the introduction of peanut butter before 12 months of age is safe. However, allergic reactions are estimated to occur in 10% of these infants and there is a risk of anaphylaxis. Facilitating introduction of peanut through supervised clinics may benefit infants with certain risk profiles. Introduction: Our laboratory has offered in vitro specific IgE testing for [Thermofisher Phadia ImmunoCAP] galactose-1,3-alpha-galactose (alpha-gal) for more than ten years. During this time, clinicians have used a variety of testing strategies to (i) confirm sensitisation; (ii) assess risk of reactions to tick bites or ingestion of meat; and, (iii) assess likely success of reintroduction of meat and if excluded, dairy. The laboratory accepted the Medicare rebate for this testing apart from alpha-gal due to its reagent cost exceeding the rebate. Fox suppression programs have resulted in marked expansion of bandicoot populations in the northern half of Sydney with a consequent marked increase in humans exposed to multiple tick bites on multiple occasions. Our clinical experience has been that 40% of persons may return to eating meat after successful tick bite and meat avoidance over 12-36 months. We wanted to determine the incidence of alpha-gal tests, the frequency of positive tests and the rates of follow up testing. We further wanted to assess the impact of a prior positive result on future test results in terms of increasing, similar or decreasing sensitisation.
Methods: We interrogated our laboratory dataset for the 10 years prior to July 2018 to determine the number of requests for specific IgE to alphagal, co-requested allergy requests as well as patterns of follow up test requests. We then analysed the results of initial and subsequent tests for increasing or decreasing sensitisation over time. We only analysed data that included alphagal testing on each occasion, excluding persons who only had meat testing. 
